Adjuvant systemic therapy for primary breast cancer

F. J. Esteva; G. N. Hortobagyi

doi:10.1016/S0039-6109(05)70062-1

Adjuvant systemic therapy for primary breast cancer

F. J. Esteva
, G. N. Hortobagyi

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Chemotherapy and tamoxifen will continue to play an important role in the treatment of patients with primary breast cancer. Future clinical trials will clarify the role of HDCT for patients at high risk. Molecular markers of response may assist in drug selection in the adjuvant setting. Development of novel therapeutic agents continues based on an expanded biologic understanding of tumor development and progression.

Original language	English (US)
Pages (from-to)	1075-1090
Number of pages	16
Journal	Surgical Clinics of North America
Volume	79
Issue number	5
DOIs	https://doi.org/10.1016/S0039-6109(05)70062-1
State	Published - 1999

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/S0039-6109(05)70062-1

Cite this

@article{9b27a4da1432462e85b0feb2c20ce8ba,

title = "Adjuvant systemic therapy for primary breast cancer",

abstract = "Chemotherapy and tamoxifen will continue to play an important role in the treatment of patients with primary breast cancer. Future clinical trials will clarify the role of HDCT for patients at high risk. Molecular markers of response may assist in drug selection in the adjuvant setting. Development of novel therapeutic agents continues based on an expanded biologic understanding of tumor development and progression.",

author = "Esteva, \{F. J.\} and Hortobagyi, \{G. N.\}",

year = "1999",

doi = "10.1016/S0039-6109(05)70062-1",

language = "English (US)",

volume = "79",

pages = "1075--1090",

journal = "Surgical Clinics of North America",

issn = "0039-6109",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - Adjuvant systemic therapy for primary breast cancer

AU - Esteva, F. J.

AU - Hortobagyi, G. N.

PY - 1999

Y1 - 1999

N2 - Chemotherapy and tamoxifen will continue to play an important role in the treatment of patients with primary breast cancer. Future clinical trials will clarify the role of HDCT for patients at high risk. Molecular markers of response may assist in drug selection in the adjuvant setting. Development of novel therapeutic agents continues based on an expanded biologic understanding of tumor development and progression.

AB - Chemotherapy and tamoxifen will continue to play an important role in the treatment of patients with primary breast cancer. Future clinical trials will clarify the role of HDCT for patients at high risk. Molecular markers of response may assist in drug selection in the adjuvant setting. Development of novel therapeutic agents continues based on an expanded biologic understanding of tumor development and progression.

UR - https://www.scopus.com/pages/publications/0032843176

UR - https://www.scopus.com/pages/publications/0032843176#tab=citedBy

U2 - 10.1016/S0039-6109(05)70062-1

DO - 10.1016/S0039-6109(05)70062-1

M3 - Article

C2 - 10572552

AN - SCOPUS:0032843176

SN - 0039-6109

VL - 79

SP - 1075

EP - 1090

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

IS - 5

ER -

Adjuvant systemic therapy for primary breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this